Bans the sale of cosmetics developed/manufactured using animal testing. A violation would be a $1,000 fine for each offense.
H5865 amends Rhode Island’s animal cruelty laws to add a new prohibition on the sale or offer for sale in the state of cosmetics that were developed or manufactured using cosmetic animal testing. The ban applies to testing conducted or contracted by the manufacturer or its supplier on or after January 1, 2026, and it defines key terms such as cosmetic product, cosmetic ingredient, non-functional constituent, manufacturer, and supplier. The bill also updates existing cruelty definitions to include “cosmetic animal testing” and clarifies related animal welfare terms such as adequate living conditions and hazardous accumulation of animals.
The bill includes several exceptions. It does not bar cosmetics where animal testing was required by certain federal, state, or foreign regulators under specified conditions, nor does it apply to some products or ingredients tested before January 1, 2025, so long as no new prohibited testing occurs after January 1, 2026. It also preserves the ability of manufacturers to review, assess, or retain evidence from prior animal tests. A violation would carry a civil penalty of up to $1,000 per offense, with each day of a continuing violation treated as a separate offense.
This bill would expand Rhode Island’s cruelty-to-animals chapter by creating a state-level market restriction on cosmetics tied to animal testing, rather than only regulating the testing itself. It would affect cosmetic manufacturers, suppliers, and retailers that sell into Rhode Island, and it would preempt local governments from adopting non-identical rules on cosmetic animal testing. The measure also amends statutory definitions in Chapter 4-1 to incorporate cosmetic-testing terminology and to refine existing animal welfare standards.
Based on the bill text and the absence of recorded committee testimony or votes, the available record suggests a generally protective, animal-welfare-oriented policy approach with no documented opposition in the provided materials. The bill’s sponsors and caption indicate a clear intent to end the sale of cosmetics linked to animal testing, which is typically framed as a consumer and animal protection measure. Because no transcripts or vote history are included, there is no direct evidence here of broader legislative support or resistance.
The main points of potential contention are the scope of the sales ban, the treatment of products tested outside the United States, and the exceptions for regulatory-required testing and preexisting products or ingredients. Cosmetic manufacturers and suppliers may view the bill as burdensome or difficult to comply with, especially where they rely on foreign regulatory testing or legacy safety data. Animal welfare advocates would likely support the measure, while industry stakeholders may focus on the exemptions, the effective-date structure, and the $1,000-per-offense penalty as areas needing clarification or narrowing.